January 2026 in “International Journal of Pharmaceutical Quality Assurance” Alopecia Areata patients have low zinc and high copper levels.
December 2025 in “Gastroenterology Insights” IBS is linked to certain skin conditions like psoriasis and rosacea, and vice versa.
November 2025 in “Frontiers in Immunology” SQSTM1 gene issues may increase the risk of alopecia areata.
November 2025 in “Turkish Journal of Dermatology” Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
September 2025 in “Journal of Skin and Stem Cell” The combination of calcipotriol and PRP is the most effective treatment for alopecia areata.
June 2024 in “Dermatology and Therapy” Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.
May 2024 in “Frontiers in Immunology” Type-2 immunity may influence skin diseases and could be targeted for treatment.
January 2024 in “Dermatology practical & conceptual” Male gender and family history predict alopecia areata recurrence.
October 2023 in “Benha Journal of Applied Sciences” PPAR-γ may be a key target for treating alopecia areata and other skin conditions.
September 2023 in “Cureus” Early recognition and treatment of atypical alopecia areata in infants are crucial.